MXPA01013462A - Metodos y composiciones para prevenir la formacion de arn aberrante durante la transcripcion de una secuencia plasmidica. - Google Patents

Metodos y composiciones para prevenir la formacion de arn aberrante durante la transcripcion de una secuencia plasmidica.

Info

Publication number
MXPA01013462A
MXPA01013462A MXPA01013462A MXPA01013462A MXPA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A
Authority
MX
Mexico
Prior art keywords
sequence
strand
polynucleotide
terminator
molecule according
Prior art date
Application number
MXPA01013462A
Other languages
English (en)
Spanish (es)
Inventor
C Satishchandran
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA01013462A publication Critical patent/MXPA01013462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA01013462A 1999-07-09 2000-06-27 Metodos y composiciones para prevenir la formacion de arn aberrante durante la transcripcion de una secuencia plasmidica. MXPA01013462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14305999P 1999-07-09 1999-07-09
PCT/US2000/017670 WO2001004313A1 (fr) 1999-07-09 2000-06-27 Methodes et compositions empechant la formation d'un arn aberrant pendant la transcription d'une sequence plasmidique

Publications (1)

Publication Number Publication Date
MXPA01013462A true MXPA01013462A (es) 2002-07-02

Family

ID=22502421

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01013462A MXPA01013462A (es) 1999-07-09 2000-06-27 Metodos y composiciones para prevenir la formacion de arn aberrante durante la transcripcion de una secuencia plasmidica.

Country Status (10)

Country Link
EP (1) EP1194556A1 (fr)
JP (1) JP2003504061A (fr)
KR (1) KR20020030780A (fr)
CN (1) CN1360631A (fr)
AU (1) AU783681B2 (fr)
BR (1) BR0012325A (fr)
CA (1) CA2378653A1 (fr)
IL (1) IL147026A0 (fr)
MX (1) MXPA01013462A (fr)
WO (1) WO2001004313A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CZ295108B6 (cs) 1998-03-20 2005-05-18 Benitec Australia Ltd Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
EP2314700A1 (fr) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition et méthode destinées à l'attenuation in vivo et in vitro de l'expression génique utilisant de l'ARN double brin
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2001068835A2 (fr) * 2000-03-13 2001-09-20 Aptagen Technique de modification d'un acide nucleique
CA2369944A1 (fr) 2001-01-31 2002-07-31 Nucleonics Inc. Utilisation de l'inhibition genetique post-transcriptionnelle pour identifier les sequences d'acides nucleiques qui modulent la fonction d'une cellule
WO2002077609A2 (fr) 2001-03-26 2002-10-03 Message Pharmaceuticals, Inc. Identification de composes utiles dans le traitement ou la prevention des maladies proliferatives
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1604688B1 (fr) 2001-06-05 2010-02-03 CureVac GmbH ARNm stabilisé codant pour un antigène tumoral avec un contenu G/C augmenté
US7897382B2 (en) 2001-10-22 2011-03-01 Alnylam Pharmaceuticals, Inc. Transfection kinetics and structural promoters
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
EP1623009A4 (fr) * 2003-04-22 2008-02-13 Nucleonics Inc Cinetique de transfection et promoteurs structuraux
CA2554212A1 (fr) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Inhibition induite par l'interference arn de l'expression genetique, a l'aide d'un acide nucleique interferant court multifonctionnel (sina multifonctionnel)
US20060019914A1 (en) 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005222965B8 (en) 2004-03-15 2010-07-01 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2557532A1 (fr) 2004-04-23 2005-11-10 Angela M. Christiano Inhibition d'un arnm associe a une proteine du gene hairless (sans poil)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2579574A1 (fr) 2004-07-23 2007-01-04 The University Of North Carolina At Chapel Hill Procedes et materiaux pour determiner la sensibilite a la douleur et prevoir et traiter des troubles apparentes
US8703769B2 (en) 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
EP1931789B1 (fr) 2005-09-20 2016-05-04 BASF Plant Science GmbH Methodes de regulation de l'expression genique utilisant ta-siarn
CA2676143A1 (fr) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification de composants a base d' exosome utilises comme vaccin
BRPI0809130A8 (pt) 2007-03-21 2021-11-03 Brookhaven Science Ass Llc Composições combinadas hairpin-antissenso e métodos para modulação da expressão
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
BR112014016870A2 (pt) 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2834259A4 (fr) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Polynucléotides modifiés
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2892529C (fr) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Arn modifie a son extremite terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite
CA2925021A1 (fr) 2013-11-01 2015-05-07 Curevac Ag Arn modifie a proprietes immunostimulantes reduites
WO2017152073A1 (fr) 2016-03-04 2017-09-08 University Of Louisville Research Foundation, Inc. Procédés et compositions pour l'expansion ex vivo de très petites cellules souches de type embryonnaire (vsel)
WO2020236597A1 (fr) * 2019-05-17 2020-11-26 Massachusetts Institute Of Technology Arn post-signal de poly(a) modifié et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587300A (en) * 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1999010509A1 (fr) * 1997-08-22 1999-03-04 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services, National Institutes Of Health Nucleotides inhibiteurs de la destabilisation et de la sequestration de l'arn
US20030083272A1 (en) * 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy

Also Published As

Publication number Publication date
JP2003504061A (ja) 2003-02-04
BR0012325A (pt) 2002-05-21
CN1360631A (zh) 2002-07-24
AU783681B2 (en) 2005-11-24
KR20020030780A (ko) 2002-04-25
EP1194556A1 (fr) 2002-04-10
AU5893700A (en) 2001-01-30
WO2001004313A1 (fr) 2001-01-18
IL147026A0 (en) 2002-08-14
CA2378653A1 (fr) 2001-01-18

Similar Documents

Publication Publication Date Title
AU783681B2 (en) Methods and compositions for preventing the formation of aberrant RNA during transcription of a plasmid sequence
EP2646556B1 (fr) Nouveau promoteur hybride et vecteur recombinant le comprenant
KR20180117171A (ko) 비-바이러스 유전자 전달을 위한 폐쇄형-말단 선형 듀플렉스 dna
EP3768846B1 (fr) Vecteurs nanoplasmidiques viraux et non viraux à production améliorée
EP1583832A2 (fr) Constructions geniques permettant l'expression inductible de petites molecules d'arn pour une extinction genique ciblee
EP2497830A1 (fr) Systèmes d'expression régulée
US6342596B1 (en) Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
CN117545842A (zh) SMN1和miR-23a在治疗脊髓性肌萎缩中的协同效应
EP1814906A1 (fr) Circuits moleculaires regulateurs permettant l'activation soutenue de genes d'interet au moyen d'un stress unique
KR101442254B1 (ko) 최적의 진핵 세포 발현 벡터의 개발
CN113874512A (zh) 诱导毛细胞分化的组合物和方法
US20060171924A1 (en) Bidirectional promoters for small RNA expression
US20020086427A1 (en) Inducible eukaryotic expression system that regulates protein translation
WO2002022786A1 (fr) Procede et composition cellulaire pour composants de depistage d'une activite anti-inflammatoire
TWI260346B (en) Internal ribosome entry site of the labial gene for protein expression
US20050266488A1 (en) Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins
JP2006506044A (ja) タンパク質分泌ダイナミクスの加速のための組成物及び方法
JP2002519059A (ja) ミオスタチン遺伝子の新規なプロモーター配列
WO2022166771A1 (fr) Procédé de construction de 3'utr et application
JP2003523182A (ja) 哺乳動物遺伝子発現を調節するための分子スイッチ
KR102590276B1 (ko) 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도
WO2023055192A1 (fr) Composition pour l'amélioration de l'ancrage et de l'efficacité de culture d'une cellule, et son utilisation
US20230374526A1 (en) Forskolin-inducible promoters and hypoxia-inducible promoters
WO2002050264A2 (fr) Promoteurs, et constructions d'expression, destines a une expression recombinante
Nordstrom Expression plasmids for non-viral gene therapy